1. Market Research
  2. > Lupus Erythematosus – Pipeline Review, H1 2013

Lupus Erythematosus – Pipeline Review, H1 2013

  • March 2013
  • -
  • Global Markets Direct
  • -
  • 238 pages

Lupus Erythematosus – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Lupus Erythematosus - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Lupus Erythematosus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lupus Erythematosus. Lupus Erythematosus - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Lupus Erythematosus.
- A review of the Lupus Erythematosus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Lupus Erythematosus pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Lupus Erythematosus.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Lupus Erythematosus pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Lupus Erythematosus - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Lupus Erythematosus Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Lupus Erythematosus 11
Lupus Erythematosus Therapeutics under Development by Companies 13
Lupus Erythematosus Therapeutics under Investigation by Universities/Institutes 18
Late Stage Products 19
Comparative Analysis 19
Mid Clinical Stage Products 20
Comparative Analysis 20
Early Clinical Stage Products 21
Comparative Analysis 21
Discovery and Pre-Clinical Stage Products 22
Comparative Analysis 22
Lupus Erythematosus Therapeutics - Products under Development by Companies 23
Lupus Erythematosus Therapeutics - Products under Investigation by Universities/Institutes 28
Companies Involved in Lupus Erythematosus Therapeutics Development 29
Amgen Inc. 29
Sanofi-Aventis 30
Eli Lilly and Company 31
GlaxoSmithKline plc 32
Genentech, Inc. 33
MedImmune LLC 34
Biotest AG 35
Novo Nordisk A/S 36
Isotechnika Pharma Inc. 37
Pfizer Inc. 38
Rigel Pharmaceuticals, Inc. 39
Teva Pharmaceutical Industries Limited 40
UCB Group 41
Hadasit Medical Research Services and Development Ltd 42
Celgene Corporation 43
Onyx Pharmaceuticals, Inc. 44
Merck KGaA 45
4SC AG 46
Genesis Research and Development Corporation Ltd. 47
Hollis-Eden Pharmaceuticals, Inc. 48
Active Biotech AB 49
IMMUNOMEDICS, INC 50
Idera Pharmaceuticals, Inc. 51
Portola Pharmaceuticals, Inc. 52
Pharmacyclics, Inc. 53
Dynavax Technologies Corporation 54
Hansa Medical AB 55
Immupharma Plc 56
Farmacija d.o.o. Tuzla 57
CREABILIS Therapeutics S.r.l. 58
Argos Therapeutics, Inc. 59
MacroGenics, Inc. 60
Astion Pharma A/S 61
Five Prime Therapeutics, Inc. 62
Vaccinex, Inc. 63
Kineta, Inc. 64
Theraclone Sciences, Inc. 65
Biotica Technology Ltd 66
Cornerstone Therapeutics Inc. 67
CBio Limited 68
Anthera Pharmaceuticals‚ Inc. 69
KYORIN Pharmaceutical Co., Ltd. 70
SuppreMol GmbH 71
NasVax Ltd. 72
Amplimmune, Inc. 73
Lycera Corp. 74
Lupus Erythematosus - Therapeutics Assessment 75
Assessment by Monotherapy Products 75
Assessment by Combination Products 76
Assessment by Route of Administration 77
Assessment by Molecule Type 79
Drug Profiles 82
laquinimod sodium - Drug Profile 82
forigerimod - Drug Profile 84
AMG-811 - Drug Profile 86
AMG-557 - Drug Profile 87
atacicept - Drug Profile 88
rontalizumab - Drug Profile 92
tabalumab - Drug Profile 93
belimumab - Drug Profile 95
sifalimumab - Drug Profile 98
tanzisertib - Drug Profile 100
CC-11050 - Drug Profile 102
IMO-3100 - Drug Profile 103
paquinimod - Drug Profile 105
PCI-45261 - Drug Profile 106
PD-360324 - Drug Profile 107
PF-04236921 - Drug Profile 108
BT-063 - Drug Profile 110
AGS-009 - Drug Profile 111
VX-5 - Drug Profile 113
HE-3286 - Drug Profile 114
interferon alfa-n1 - Drug Profile 116
CDP-7657 - Drug Profile 117
blisibimod - Drug Profile 119
AMP-110 - Drug Profile 121
ONX-0914 - Drug Profile 123
vidofludimus - Drug Profile 124
nPT-mTOR - Drug Profile 128
Zyrogen Antibody - Drug Profile 129
CT-637 - Drug Profile 130
KRP-203 - Drug Profile 131
MEDI-546 - Drug Profile 133
HMGB1 Monoclonal Antibody - Drug Profile 134
DV-1179 - Drug Profile 136
epratuzumab - Drug Profile 137
levosalbutamol - Drug Profile 141
INV-103 - Drug Profile 142
PRT-062607 - Drug Profile 144
SM-101 - Drug Profile 145
Anti-ILT7 - Drug Profile 147
Anti-aCD3 Mab - Drug Profile 148
GSK-2586184 - Drug Profile 150
NN-8828 - Drug Profile 152
Leukothera - Drug Profile 154
ShK-186 - Drug Profile 155
DART (CD32B x CD79B) - Drug Profile 157
Bioenergetics Program - Drug Profile 158
Cytokine-Like Proteins - Drug Profile 159
MesoStem - Drug Profile 160
AMG-729 - Drug Profile 161
IMO-8400 - Drug Profile 162
R-333 - Drug Profile 164
EndoS - Drug Profile 165
ABK-16 - Drug Profile 166
Syk-Specific Backups - Drug Profile 167
GX-101 - Drug Profile 168
SAR-113244 - Drug Profile 169
Respiratory, Inflammation And Autoimmunity Program - Drug Profile 170
RSLV-132 - Drug Profile 171
Drug For Respiratory, Inflammation And Autoimmunity 1 - Drug Profile 172
Drug For Respiratory, Inflammation And Autoimmunity 2 - Drug Profile 173
Multiple Lead Series Targeting IRAK4 - Drug Profile 174
RORgammat Inhibitors - Drug Profile 175
metenkefalin + tridecactide - Drug Profile 176
ND-2110 - Drug Profile 177
ND-2158 - Drug Profile 179
ND-346 - Drug Profile 181
Peptides For Systemic Lupus Erythematosus - Drug Profile 182
Y-27 - Drug Profile 183
caffeic acid phenethyl ester - Drug Profile 184
RSLV-133 - Drug Profile 186
Other Bi Specific Nucleases - Drug Profile 187
P-13 - Drug Profile 188
KPT-355 - Drug Profile 189
Lupus Erythematosus Therapeutics - Drug Profile Updates 190
Lupus Erythematosus Therapeutics - Discontinued Products 221
Lupus Erythematosus Therapeutics - Dormant Products 222
Lupus Erythematosus - Product Development Milestones 225
Featured News and Press Releases 225
Appendix 232
Methodology 232
Coverage 232
Secondary Research 232
Primary Research 232
Expert Panel Validation 232
Contact Us 233
Disclaimer 233



List of Tables

Number of Products Under Development for Lupus Erythematosus, H1 2013 16
Products under Development for Lupus Erythematosus - Comparative Analysis, H1 2013 17
Number of Products under Development by Companies, H1 2013 19
Number of Products under Development by Companies, H1 2013 (Contd..1) 20
Number of Products under Development by Companies, H1 2013 (Contd..2) 21
Number of Products under Development by Companies, H1 2013 (Contd..3) 22
Number of Products under Investigation by Universities/Institutes, H1 2013 23
Comparative Analysis by Late Stage Development, H1 2013 24
Comparative Analysis by Mid Clinical Stage Development, H1 2013 25
Comparative Analysis by Early Clinical Stage Development, H1 2013 26
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 27
Products under Development by Companies, H1 2013 28
Products under Development by Companies, H1 2013 (Contd..1) 29
Products under Development by Companies, H1 2013 (Contd..2) 30
Products under Development by Companies, H1 2013 (Contd..3) 31
Products under Development by Companies, H1 2013 (Contd..4) 32
Products under Investigation by Universities/Institutes, H1 2013 33
Amgen Inc., H1 2013 34
Sanofi-Aventis, H1 2013 35
Eli Lilly and Company, H1 2013 36
GlaxoSmithKline plc, H1 2013 37
Genentech, Inc., H1 2013 38
MedImmune LLC, H1 2013 39
Biotest AG, H1 2013 40
Novo Nordisk A/S, H1 2013 41
Isotechnika Pharma Inc., H1 2013 42
Pfizer Inc., H1 2013 43
Rigel Pharmaceuticals, Inc., H1 2013 44
Teva Pharmaceutical Industries Limited, H1 2013 45
UCB Group, H1 2013 46
Hadasit Medical Research Services and Development Ltd, H1 2013 47
Celgene Corporation, H1 2013 48
Onyx Pharmaceuticals, Inc., H1 2013 49
Merck KGaA, H1 2013 50
4SC AG, H1 2013 51
Genesis Research and Development Corporation Ltd., H1 2013 52
Hollis-Eden Pharmaceuticals, Inc., H1 2013 53
Active Biotech AB, H1 2013 54
IMMUNOMEDICS, INC, H1 2013 55
Idera Pharmaceuticals, Inc., H1 2013 56
Portola Pharmaceuticals, Inc., H1 2013 57
Pharmacyclics, Inc., H1 2013 58
Dynavax Technologies Corporation, H1 2013 59
Hansa Medical AB, H1 2013 60
Immupharma Plc, H1 2013 61
Farmacija d.o.o. Tuzla, H1 2013 62
CREABILIS Therapeutics S.r.l., H1 2013 63
Argos Therapeutics, Inc., H1 2013 64
MacroGenics, Inc., H1 2013 65
Astion Pharma A/S, H1 2013 66
Five Prime Therapeutics, Inc., H1 2013 67
Vaccinex, Inc., H1 2013 68
Kineta, Inc., H1 2013 69
Theraclone Sciences, Inc., H1 2013 70
Biotica Technology Ltd, H1 2013 71
Cornerstone Therapeutics Inc., H1 2013 72
CBio Limited, H1 2013 73
Anthera Pharmaceuticals‚ Inc., H1 2013 74
KYORIN Pharmaceutical Co., Ltd., H1 2013 75
SuppreMol GmbH, H1 2013 76
NasVax Ltd., H1 2013 77
Amplimmune, Inc., H1 2013 78
Lycera Corp., H1 2013 79
Assessment by Monotherapy Products, H1 2013 80
Assessment by Combination Products, H1 2013 81
Assessment by Stage and Route of Administration, H1 2013 83
Assessment by Stage and Molecule Type, H1 2013 86
Lupus Erythematosus Therapeutics - Drug Profile Updates 195
Lupus Erythematosus Therapeutics - Discontinued Products 226
Lupus Erythematosus Therapeutics - Dormant Products 227
Lupus Erythematosus Therapeutics - Dormant Products (Contd..1) 228
Lupus Erythematosus Therapeutics - Dormant Products (Contd..2) 229



List of Figures

Number of Products under Development for Lupus Erythematosus, H1 2013 16
Products under Development for Lupus Erythematosus - Comparative Analysis, H1 2013 17
Products under Development by Companies, H1 2013 18
Products under Investigation by Universities/Institutes, H1 2013 23
Late Stage Products, H1 2013 24
Mid Clinical Stage Products, H1 2013 25
Early Clinical Stage Products, H1 2013 26
Discovery and Pre-Clinical Stage Products, H1 2013 27
Assessment by Monotherapy Products, H1 2013 80
Assessment by Combination Products, H1 2013 81
Assessment by Route of Administration, H1 2013 82
Assessment by Stage and Route of Administration, H1 2013 83
Assessment by Molecule Type, H1 2013 84
Assessment by Stage and Molecule Type, H1 2013 85

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.